Alcoholic Hepatiti Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL ALCOHOLIC HEPATITI DRUG INDUSTRY

2.1 Summary about Alcoholic Hepatiti Drug Industry

2.2 Alcoholic Hepatiti Drug Market Trends

2.2.1 Alcoholic Hepatiti Drug Production & Consumption Trends

2.2.2 Alcoholic Hepatiti Drug Demand Structure Trends

2.3 Alcoholic Hepatiti Drug Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 F-652

4.2.2 GRI-0621

4.2.3 HepaStem

4.2.4 IMM-124E

4.2.5 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospital

4.3.2 Clinic

4.3.3 Others

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 F-652

5.2.2 GRI-0621

5.2.3 HepaStem

5.2.4 IMM-124E

5.2.5 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospital

5.3.2 Clinic

5.3.3 Others

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 F-652

6.2.2 GRI-0621

6.2.3 HepaStem

6.2.4 IMM-124E

6.2.5 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospital

6.3.2 Clinic

6.3.3 Others

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 F-652

7.2.2 GRI-0621

7.2.3 HepaStem

7.2.4 IMM-124E

7.2.5 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospital

7.3.2 Clinic

7.3.3 Others

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 F-652

8.2.2 GRI-0621

8.2.3 HepaStem

8.2.4 IMM-124E

8.2.5 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospital

8.3.2 Clinic

8.3.3 Others

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 F-652

9.2.2 GRI-0621

9.2.3 HepaStem

9.2.4 IMM-124E

9.2.5 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospital

9.3.2 Clinic

9.3.3 Others

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Alfact Innovation

10.1.2 Generon (Shanghai) Corp Ltd

10.1.3 Gilead Sciences Inc

10.1.4 GRI Bio Inc

10.1.5 Immuron Ltd

10.1.6 Intercept Pharmaceuticals Inc

10.1.7 Promethera Biosciences SA

10.1.8 Verlyx Pharma Inc

10.1.9 Vital Therapies Inc

10.2 Alcoholic Hepatiti Drug Sales Date of Major Players (2017-2020e)

10.2.1 Alfact Innovation

10.2.2 Generon (Shanghai) Corp Ltd

10.2.3 Gilead Sciences Inc

10.2.4 GRI Bio Inc

10.2.5 Immuron Ltd

10.2.6 Intercept Pharmaceuticals Inc

10.2.7 Promethera Biosciences SA

10.2.8 Verlyx Pharma Inc

10.2.9 Vital Therapies Inc

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

1.Table Alcoholic Hepatiti Drug Product Type Overview

2.Table Alcoholic Hepatiti Drug Product Type Market Share List

3.Table Alcoholic Hepatiti Drug Product Type of Major Players

4.Table Brief Introduction of Alfact Innovation

5.Table Brief Introduction of Generon (Shanghai) Corp Ltd

6.Table Brief Introduction of Gilead Sciences Inc

7.Table Brief Introduction of GRI Bio Inc

8.Table Brief Introduction of Immuron Ltd

9.Table Brief Introduction of Intercept Pharmaceuticals Inc

10.Table Brief Introduction of Promethera Biosciences SA

11.Table Brief Introduction of Verlyx Pharma Inc

12.Table Brief Introduction of Vital Therapies Inc

13.Table Products & Services of Alfact Innovation

14.Table Products & Services of Generon (Shanghai) Corp Ltd

15.Table Products & Services of Gilead Sciences Inc

16.Table Products & Services of GRI Bio Inc

17.Table Products & Services of Immuron Ltd

18.Table Products & Services of Intercept Pharmaceuticals Inc

19.Table Products & Services of Promethera Biosciences SA

20.Table Products & Services of Verlyx Pharma Inc

21.Table Products & Services of Vital Therapies Inc

22.Table Market Distribution of Major Players

23.Table Global Major Players Sales Revenue (Million USD) 2017-2020e

24.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

25.Table Global Alcoholic Hepatiti Drug Market Forecast (Million USD) by Region 2021f-2026f

26.Table Global Alcoholic Hepatiti Drug Market Forecast (Million USD) Share by Region 2021f-2026f

27.Table Global Alcoholic Hepatiti Drug Market Forecast (Million USD) by Demand 2021f-2026f

28.Table Global Alcoholic Hepatiti Drug Market Forecast (Million USD) Share by Demand 2021f-2026f